SCHEMBL5282245

SCHEMBL5282245

Cc1[nH]nnc1C(F)(F)F

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.31
NR2F2 P24468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5283651 0.81
SCHEMBL5281237 0.77
SCHEMBL5279864 0.72
SCHEMBL1598544 0.72
SCHEMBL5278959 0.71
SCHEMBL5279708 0.71
SCHEMBL5275933 0.71
SCHEMBL5273493 0.70
SCHEMBL5281997 0.70
SCHEMBL5277608 0.70 HCAR3 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-10-21 US disclosed
EP-3822272-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-05-19 EP disclosed
WO-2020011254-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR 正大天晴药业集团股份有限公司 2020-01-16 WO disclosed
WO-2011050160-A1 PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC MA INC. (US) 2011-04-28 WO disclosed
EP-1859781-A2 Brightening and/or colouring agent with triazoles Henkel Kommanditgesellschaft auf Aktien (DE) 2007-11-28 EP disclosed
US-7276567-B2 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-02 US disclosed
US-20050261449-A1 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENT INC. 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR PDE3B, PDE4A, PDE3A COMT 1230/4885NR2F2 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.